On October 19, 2026, the U.S. Food and Drug Administration approved the first generic of Climara Pro. The product is Zydus Pharmaceuticals (USA)'s estradiol and levonorgestrel transdermal system, which delivers 0.045 mg estradiol and 0.015 mg levonorgestrel per day from a patch changed once a week. The FDA announced it on October 20. The generic is rated therapeutically equivalent to Bayer's brand and has the same two indications: moderate-to-severe vasomotor symptoms of menopause and prevention of postmenopausal osteoporosis. It is approved only for women with an intact uterus. The progestogen is there to protect the uterine lining from the overgrowth that estrogen on its own can cause.

Why It Matters

This approval doesn't fix the [estradiol-patch supply crunch](/stories/estradiol-patch-shortage-fda-action), which mainly involves estrogen-only products. It does add a cheaper source in the transdermal combination category, at a time when demand is high for several reasons. The FDA [removed the black-box warning](/stories/hrt-shortage-fda-warning-removal) on HRT. [ACP and ACOG](/stories/acp-menopause-hormone-therapy-first-line) now put hormone therapy first for vasomotor symptoms. And Denmark's national registry data in [The BMJ](/stories/bmj-oral-hrt-clot-risk-transdermal) linked HRT's clot risk to oral rather than transdermal routes. For telehealth menopause platforms such as Hers, Midi and Evernow, a generic once-weekly combination patch is a lower-cost product to offer women who still have a uterus. A cheaper product makes subscription pricing easier to sell to customers. The policy signal is the second takeaway. Between the [executive order creating an NIH women's-health division](/stories/trump-womens-health-executive-order-nih), the FDA's [testosterone-for-women workshop](/stories/fda-testosterone-women-workshop) and now a generic approval announced as a public-health priority, menopause has become an area where federal agencies are visibly competing for credit. For brands selling menopause-adjacent sexual-wellness products, from vaginal moisturisers to [air-pulse "menopause" devices](/stories/lovehoney-sheherme-menopulse-boots), that attention means more marketing tailwind. It also means closer scrutiny of any claim that sounds like treatment.

The FDA presented the approval as an affordability measure. "Menopause is a universal experience for women, and it can greatly affect a person's quality of life. This approval makes effective treatment more accessible," said Acting Commissioner Kyle Diamantas. CDER director Michael Davis, MD, PhD, said once-weekly dosing "can make a real difference," because a patch "may help patients stay on track" compared with a daily pill. The agency points out that nine out of 10 U.S. prescriptions filled are generics. It also notes that this product is a combination patch and so differs from the estrogen-only patches most commonly used in menopause care. Contraindications are unchanged from the brand and include current or past breast cancer, active or past DVT/PE, and thrombophilic disorders.

Drug Topics places the approval within this month's federal attention on menopause, including the White House executive order and the professional shift toward lower-dose transdermal routes. It also notes that the evidence on oral hormone therapy's clot risk is pushing prescribing toward patches. The FDA asks patients to contact Zydus about availability. No launch date or price was disclosed.

Sources

Update — 2026-10-22

Initial entry — story first created.